On the one hand, the downregulation of miRNAs such as miR-106a can result in the enhanced apoptosis of podocyte through targeting PTEN and BCL2L11, leading to the loss of podocyte and development of FSGS. The gene discussed is BCL2L11; the disease is focal segmental glomerulosclerosis.